Nuclear Medicine
Videos
Selected Videos:
- Urotoday – April 15, 2025
Jeremie Calais, MD, on the overview of Clinical Trials of PSMA RPT in 2025 - Urology Times – December 10, 2024
Jeremie Calais, MD, on development of a prostate cancer imaging reporting template - Urology Times – November 27, 2024
Jeremie Calais, MD, on rationale for reporting template for PSMA-PET scans - Urology Times – November 12, 2024
Jeremie Calais, MD, highlights study of PSMA-PET vs bone scan in metastatic prostate cancer - Diagnostic Imaging – Sept 4, 2024
PSMA PET in Clinical Practice: Optimizing Prostate Cancer Management - GU oncology Now – June 20, 2024
Nuclear Medicine Highlights From the SNMMI 2024 Annual Meeting
SNMMI 2024: Dosimetry of 177Lu-PSMA RLTs, FLEX-MRT, and More - GU oncology Now – March 21, 2024
Impact of PSMA PET/CT on Prostate Cancer Salvage Radiotherapy Management
PSMA PET for BCR Salvage RT Management: Projecting Survival Data and Additional Research Avenues - GU oncology Now – March 21, 2024
PSMA-dRT: Imaging Prior to Radiation for Intermediate-, High-Risk Prostate Cancer - OncLive – March 12, 2024
Controversies in the Treatment of Patients with Prostate Cancer - Urotoday – January 30, 2024
Highlights: UCLA/UCSF Inaugural PSMA PET and RLT Conference - Jeremie Calais - GU oncology Now – January 24, 2024
Dr. Jérémie Calais Discusses PSMA-RLT and the 2024 PSMA Conference - GU oncology Now – October 31, 2023
Comparing Sensitivity, Accuracy of Bone Scans Versus PSMA PET Imaging - Part 1
Comparing Sensitivity, Accuracy of Bone Scans Versus PSMA PET Imaging - Part 2 - GU oncology Now – July 25, 2023
Novel Radiotracer That Detects, Differentiates Renal Cell Carcinomas - Diagnostic Imaging – SNMMI 2023
New Research Shows Viability of PET Imaging Agent for Clear Cell Renal Cell Carcinoma - GU oncology Now – ASCO 2023
PSMA PET Guided Salvage Radiotherapy for Prostate Cancer Post-Prostatectomy - Urotoday – ASCO 2023
PSMA PET's Influence on Prostate Cancer Studies - VJOncology – ASCO 2023
PSMA PET guided salvage RT among patients with prostate cancer in the post-prostatectomy setting
Integrating radioligand therapy for prostate cancer in US clinical practice
PSMA PET ratio predicts response to [177Lu]PSMA radioligand therapy: a multicenter study - GU oncology Now – April 20, 2023
Ongoing Supply Shortages for Lutetium-177–PSMA-617 - Urotoday - PSMA PET Academy - Case Discussion:
PSMA for Biochemical Recurrence and SRT Planning - Jeremie Calais, Michael Morris, & Alberto Briganti - OncLive – US PROST8 Conference
The Role of PSMA-PET Imaging in mCRPC - UCLA Health – Jun 8, 2022
PSMA-Targeted Prostate Biopsy
D Kuppermann, J Calais, L Marks - Urotoday - ASCO 2022
PSMA PET Imaging in Clinical Practice - Thomas Hope & Jeremie Calais - CURE Today
Educated Patient® Prostate Cancer Summit Novel Imaging Strategies - CURE Today
Radiopharmaceutical Therapy Targeting PSMA for Prostate Cancer - eCancer
FAP-targeted molecular radiotherapy in cancer patients - DocWire News
FAP-Targeted PET Imaging and Molecular Radiotherapy in Cancer Patients - eCancer
FAP-targeted PET imaging in cancer patients - Prostate Forum of Orange County
Drs. Auerbach and Calais "Theranostics: Imaging and Treatment of Prostate Cancer" - Urotoday - PSMA PET Academy
Understanding Physiological PSMA Biodistribution - Malecare.org
FAPI Theranostics for Prostate Cancer - Informed Prostate Cancer Support Group
PSMA theranostics - VJOncology – AACR2021
PSMA dRT: PSMA PET/CT before radiotherapy in prostate cancer
Wil FAPI PET/CT replace FDG PET/CT in the next decade?
Validation of FAPi PET biodistribution - Urotoday
The Impact on Patient Care and Clinical Outcomes Gallium 68 PSMA-11 in Suspected Prostate Cancer Metastasis - VuMedi
Prostate Cancer PET Imaging Biological Target: FACBC vs PSMA PET/CT - Which Option Should Be the Imaging Modality of Choice in Patients With post-RP early BCR? What Is the Best PET Target for Early Biochemical Recurrence of Prostate Cancer?
PSMA PET/CT Imaging in Prostate Cancer: GALLIUM-68 vs FLUOR-18 PSMA-PET - Which Option Matters for Detection/Localization of Disease? What Is the Impact on Drug Indication?
PSMA PET Imaging for Primary Staging: Efficacy Analysis of Methods for Ruling-out N1 and M1b Disease? - VJOncology – PROSCA/BLADDR 2020
Future of imaging and theranostics in prostate cancer - VuMedi – ASCO 2020
2020 ASCO Update on mCRPC: What Is the OS After 177Lu-PSMA-617 Molecular Radiotherapy? - eCancer – ASCO GU San Francisco 2020
Prostate-specific membrane antigen PET: Who should undergo advanced imaging? - VJOncology – ASCO GU San Francisco 2020
The significant impact of PSMA-PET on prostate cancer staging and management - SNMMIChannel – Best Clinical Investigation of the Month (Sep. 2019)
PET Offers More Precise Screening Method to Select Candidates for Neuroendocrine Tumor Therapy - VJOncology – ASCO Chicago 2019
PSMA vs AXUMIN PET/CT in prostate cancer
Molecular imaging for prostate cancer salvage radiotherapy planning
Challenges with novel molecular imaging techniques for prostate cancer - Targeted Oncology – AUA Chicago 2019
Analyzing Responses to 177LuPSMA-617 in Patients With Metastatic CRPC - Urotoday – Video Lectures - Imaging: Prostate Cancer
Advancements in PSMA PET/CT Imaging – Phillip Koo and Jeremie Calais - VJOncology – ASCO GU San Francisco 2019
Gallium-labelled PSMA-11 PET/CT and it’s benefits
Fluorine-18 FACBC vs. Gallium-labelled PSMA-11 PET/CT for prostate cancer screening
Prostate cancer radiotherapy planning with Gallium-labelled PSMA-11 PET/CT imaging - Urotoday – ASCO GU San Francisco 2019
Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning Urotoday - PCF Carlsbad 2018
Effectiveness and Resistance to PSMA Targeted RadioLigand Therapy using 177 Lu-PSMA-617Podcasts
- VJOncology Podcast
08.11.2023 Targeted radionuclide therapy in prostate cancer - GU Cast PROSPECT Summer Series | Episode 1
12.23.2020 Professor Declan Murphy
“non-metastatic (M0)" castration-resistant prostate cancer (CRPC) and PSMA PET/CT